Free Trial
→ July 2025 Rule Change to Impact Retirement Investors (From Premier Gold Co) (Ad) Buy ELVN Stock  Free ELVN Stock Alerts

Enliven Therapeutics (ELVN) Financials

Enliven Therapeutics logo
$16.21 -0.19 (-1.14%)
As of 02:12 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.
Compare
Annual Income Statements for Enliven Therapeutics

Annual Income Statements for Enliven Therapeutics

This table shows Enliven Therapeutics' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2024 2023 2022 2021 2020 2019
Period end date 12/31/2024 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Net Income / (Loss) Attributable to Common Shareholders		 -89 -72 -38 -51 -49 -23
Consolidated Net Income / (Loss)		 -89 -72 -38 -51 -41 -23
Net Income / (Loss) Continuing Operations		 -89 -72 -38 -51 -41 -23
Total Pre-Tax Income 		-89 -72 -38 -51 -41 -23
Total Operating Income		 -105 -84 -39 -51 -42 -24
Total Gross Profit		 0.00 0.00 0.00 0.00 0.00 0.00
Total Revenue		 0.00 0.00 0.00 0.00 0.00 0.00
Total Cost of Revenue		 0.00 0.00 0.00 0.00 0.00 0.00
Total Operating Expenses		 105 84 39 51 42 24
Selling, General & Admin Expense		 24 19 7.77 13 9.54 5.11
Research & Development Expense		 81 65 31 38 32 19
Total Other Income / (Expense), net		 16 12 1.13 0.06 0.34 0.65
Interest & Investment Income		 15 12 1.13 0.23 0.48 0.58
Other Income / (Expense), net		 0.87 -0.02 0.00 -0.18 -0.15 0.08
Income Tax Expense		 0.23 0.00 - 0.00 - -
Basic Earnings per Share		 ($1.89) ($2.01) ($12.05) ($2.37) ($49,218,003.53) ($33.40)
Weighted Average Basic Shares Outstanding		 47.07M 35.55M 3.12M 21.66M 13.92M 702.46K
Diluted Earnings per Share		 ($1.89) ($2.01) ($12.05) ($2.37) ($49,218,003.53) ($33.40)
Weighted Average Diluted Shares Outstanding		 47.07M 35.55M 3.12M 21.66M 13.92M 702.46K
Weighted Average Basic & Diluted Shares Outstanding		 49.00M 41.35M 26.23M 21.66M 13.92M 702.46K

Quarterly Income Statements for Enliven Therapeutics

This table shows Enliven Therapeutics' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q4 2024 Q3 2024 Q2 2024 Q1 2024 Q4 2023 Q3 2023 Q2 2023 Q1 2023 Q4 2022 Q3 2022
Period end date 12/31/2024 9/30/2024 6/30/2024 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023 12/31/2022 9/30/2022
Net Income / (Loss) Attributable to Common Shareholders		 -23 -23 -20 -23 -19 -21 -17 -15 -9.55 -11
Consolidated Net Income / (Loss)		 -23 -23 -20 -23 -19 -21 -17 -15 -9.55 -11
Net Income / (Loss) Continuing Operations		 -23 -23 -20 -23 -19 -21 -17 -15 -9.55 -11
Total Pre-Tax Income 		-23 -23 -20 -23 -19 -21 -17 -15 -9.55 -11
Total Operating Income		 -27 -27 -25 -26 -23 -24 -20 -16 -10 -11
Total Operating Expenses		 27 27 25 26 23 24 20 16 10 11
Selling, General & Admin Expense		 6.17 5.81 5.78 6.02 4.82 4.64 4.95 4.54 1.97 3.11
Research & Development Expense		 21 21 19 20 18 20 15 12 8.20 7.83
Total Other Income / (Expense), net		 3.48 3.91 4.89 3.25 3.36 3.48 3.41 1.69 0.61 0.38
Interest & Investment Income		 3.72 3.84 4.09 3.25 3.37 3.49 3.41 1.69 0.61 0.38
Basic Earnings per Share		 ($0.46) ($0.48) ($0.41) ($0.54) ($0.29) ($0.51) ($0.41) ($0.80) ($2.91) ($3.27)
Weighted Average Basic Shares Outstanding		 47.07M 48.27M 48.08M 42.05M 35.55M 41.03M 40.96M 18.51M 3.12M 3.23M
Diluted Earnings per Share		 ($0.46) ($0.48) ($0.41) ($0.54) ($0.29) ($0.51) ($0.41) ($0.80) ($2.91) ($3.27)
Weighted Average Diluted Shares Outstanding		 47.07M 48.27M 48.08M 42.05M 35.55M 41.03M 40.96M 18.51M 3.12M 3.23M
Weighted Average Basic & Diluted Shares Outstanding		 49.00M 48.86M 47.24M 47.04M 41.35M 41.21M 41.15M 41.11M 26.23M 26.29M

Annual Cash Flow Statements for Enliven Therapeutics

This table details how cash moves in and out of Enliven Therapeutics' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2024 2023 2022 2021 2020 2019
Period end date 12/31/2024 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Net Change in Cash & Equivalents		 24 25 -34 0.70 43 -2.36
Net Cash From Operating Activities		 -73 -61 -32 -47 -37 -22
Net Cash From Continuing Operating Activities		 -73 -61 -32 -47 -37 -22
Net Income / (Loss) Continuing Operations		 -89 -72 -38 -51 -41 -23
Consolidated Net Income / (Loss)		 -89 -72 -38 -51 -41 -23
Depreciation Expense		 0.32 0.30 0.22 0.10 0.10 0.03
Amortization Expense		 0.42 -4.60 0.00 0.16 0.12 -0.02
Non-Cash Adjustments To Reconcile Net Income		 20 13 4.93 3.87 2.23 0.90
Changes in Operating Assets and Liabilities, net		 -4.54 1.40 0.44 0.51 1.51 0.67
Net Cash From Investing Activities		 -36 -148 -0.61 -1.63 -17 -24
Net Cash From Continuing Investing Activities		 -36 -148 -0.61 -1.63 -17 -24
Purchase of Property, Plant & Equipment		 -0.04 -0.15 -0.61 -0.01 -0.02 -0.14
Purchase of Investments		 -351 -268 0.00 -48 -64 -24
Sale and/or Maturity of Investments		 314 120 0.00 46 48 0.00
Other Investing Activities, net		 0.87 0.00 - - - -
Net Cash From Financing Activities		 133 234 -1.80 49 97 44
Net Cash From Continuing Financing Activities		 133 235 -1.80 49 97 44
Payment of Dividends		 0.00 -8.74 0.00 - - -
Issuance of Common Equity		 130 161 0.00 1.82 80 0.00
Other Financing Activities, net		 3.63 82 -1.80 0.86 1.02 0.00
Cash Income Taxes Paid		 0.23 0.00 - - - -

Quarterly Cash Flow Statements for Enliven Therapeutics

This table details how cash moves in and out of Enliven Therapeutics' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q4 2024 Q3 2024 Q2 2024 Q1 2024 Q4 2023 Q3 2023 Q2 2023 Q1 2023 Q4 2022 Q3 2022
Period end date 12/31/2024 9/30/2024 6/30/2024 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023 12/31/2022 9/30/2022
Net Change in Cash & Equivalents		 23 3.75 -52 49 26 -52 -166 217 -11 -6.30
Net Cash From Operating Activities		 -17 -12 -20 -23 -12 -16 -12 -21 -8.15 -6.45
Net Cash From Continuing Operating Activities		 -17 -12 -20 -23 -12 -16 -12 -21 -8.15 -6.45
Net Income / (Loss) Continuing Operations		 -23 -23 -20 -23 -19 -21 -17 -15 -9.55 -11
Consolidated Net Income / (Loss)		 -23 -23 -20 -23 -19 -21 -17 -15 -9.55 -11
Depreciation Expense		 0.08 0.08 0.08 0.08 0.08 0.08 0.07 0.07 0.06 0.06
Amortization Expense		 0.98 0.71 -0.60 -0.66 -1.79 -1.98 -0.83 0.00 - -
Non-Cash Adjustments To Reconcile Net Income		 5.43 5.18 4.42 4.59 3.13 3.63 4.20 2.26 0.74 2.84
Changes in Operating Assets and Liabilities, net		 -0.51 4.99 -4.38 -4.64 5.46 3.15 1.23 -8.45 0.61 1.21
Net Cash From Investing Activities		 0.73 15 -34 -18 39 -36 -152 -0.03 -0.10 -0.01
Net Cash From Continuing Investing Activities		 0.73 15 -34 -18 39 -36 -152 -0.03 -0.10 -0.01
Purchase of Investments		 -117 -57 -121 -57 -41 -76 -151 0.00 - -
Sale and/or Maturity of Investments		 117 81 77 39 80 40 - 0.00 - -
Net Cash From Financing Activities		 40 1.12 1.81 90 0.09 -0.43 -2.82 237 -2.38 0.16
Net Cash From Continuing Financing Activities		 40 1.12 1.81 90 0.65 -0.43 -2.82 237 -2.38 0.16
Issuance of Common Equity		 40 - 0.02 90 - - -1.54 163 - -
Other Financing Activities, net		 0.45 1.12 1.79 0.27 0.65 -0.43 0.03 82 -2.38 0.16

Annual Balance Sheets for Enliven Therapeutics

This table presents Enliven Therapeutics' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2024 2023 2022 2021 2020 2019
Period end date 12/31/2024 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Total Assets		 326 272 83 94 91 33
Total Current Assets		 318 266 78 93 90 31
Cash & Equivalents		 124 100 76 48 48 4.94
Restricted Cash		 0.05 0.05 0.00 - - -
Short-Term Investments		 189 153 0.00 42 41 24
Prepaid Expenses		 4.63 2.95 2.22 2.42 2.18 1.72
Other Current Assets		 0.00 10 0.00 - - -
Plant, Property, & Equipment, net		 0.46 0.74 0.89 0.25 0.35 0.44
Total Noncurrent Assets		 7.18 4.97 4.66 0.70 0.09 2.23
Other Noncurrent Operating Assets		 7.18 4.97 4.66 0.70 0.09 2.23
Total Liabilities & Shareholders' Equity		 326 272 83 94 91 33
Total Liabilities		 16 26 10 7.62 6.41 4.38
Total Current Liabilities		 16 26 9.72 7.21 6.25 4.20
Accounts Payable		 1.34 0.53 3.44 2.36 1.97 1.66
Accrued Expenses		 15 15 6.28 4.60 4.28 2.54
Other Current Liabilities		 0.00 10 0.00 0.25 0.00 -
Total Noncurrent Liabilities		 0.00 0.07 0.66 0.41 0.16 0.18
Other Noncurrent Operating Liabilities		 0.00 0.07 0.66 0.41 0.00 -
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 310 246 73 86 84 -49
Total Preferred & Common Equity		 310 246 -77 86 84 -49
Preferred Stock		 0.00 0.00 150 0.00 0.00 0.00
Total Common Equity		 310 246 -77 86 84 -49
Common Stock		 553 400 6.04 234 181 5.87
Retained Earnings		 -243 -154 -83 -147 -96 -55
Accumulated Other Comprehensive Income / (Loss)		 0.06 0.14 0.00 -0.02 0.00 0.03

Quarterly Balance Sheets for Enliven Therapeutics

This table presents Enliven Therapeutics' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2024 Q2 2024 Q1 2024 Q3 2023 Q2 2023 Q1 2023 Q3 2022
Period end date 9/30/2024 6/30/2024 3/31/2024 9/30/2023 6/30/2023 3/31/2023 9/30/2022
Total Assets		 305 327 343 274 289 303 59
Total Current Assets		 297 318 337 269 283 298 59
Cash & Equivalents		 101 97 149 74 126 292 49
Restricted Cash		 0.05 0.05 0.05 - - - -
Short-Term Investments		 191 216 171 190 152 - 6.81
Prepaid Expenses		 5.11 5.68 6.64 5.13 5.31 5.90 2.80
Other Current Assets		 0.00 0.00 10 - - - 0.00
Plant, Property, & Equipment, net		 0.55 0.63 0.68 0.81 0.87 0.85 0.00
Total Noncurrent Assets		 7.88 8.29 4.90 4.63 4.46 4.01 0.00
Other Noncurrent Operating Assets		 7.88 8.29 4.90 4.63 4.46 4.01 0.00
Total Liabilities & Shareholders' Equity		 305 327 343 274 289 303 59
Total Liabilities		 17 22 25 12 9.51 11 1.82
Total Current Liabilities		 17 22 25 12 9.15 11 1.82
Accounts Payable		 1.02 1.08 2.73 1.49 2.84 5.86 0.77
Accrued Expenses		 16 12 12 11 6.30 5.08 1.05
Other Current Liabilities		 0.00 9.20 10 - - - 0.00
Total Noncurrent Liabilities		 0.00 0.01 0.03 0.21 0.36 0.51 0.00
Other Noncurrent Operating Liabilities		 0.00 0.01 0.03 0.21 0.36 0.51 0.00
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 288 305 318 262 279 291 57
Total Preferred & Common Equity		 288 305 318 262 279 291 57
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 - 0.00
Total Common Equity		 288 305 318 262 279 291 57
Common Stock		 508 502 495 397 393 389 235
Retained Earnings		 -220 -197 -177 -135 -114 -98 -178
Accumulated Other Comprehensive Income / (Loss)		 0.24 -0.14 -0.05 -0.15 -0.11 - -0.00

Annual Metrics And Ratios for Enliven Therapeutics

This table displays calculated financial ratios and metrics derived from Enliven Therapeutics' official financial filings.

Metric 2024 2023 2022 2021 2020 2019
Period end date 12/31/2024 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Growth Metrics		 - - - - - -
Revenue Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Growth		 -17.17% -127.75% 24.90% -23.40% -73.24% 0.00%
EBIT Growth		 -24.10% -115.39% 24.85% -23.36% -74.05% 0.00%
NOPAT Growth		 -25.17% -115.33% 24.59% -23.37% -72.91% 0.00%
Net Income Growth		 -24.36% -90.07% 26.70% -24.24% -76.28% 0.00%
EPS Growth		 5.97% 83.32% -408.44% 100.00% -147,359,192.01% 0.00%
Operating Cash Flow Growth		 -19.46% -91.01% 31.42% -25.06% -70.95% 0.00%
Free Cash Flow Firm Growth		 -42.85% -86.82% 19.01% -40.00% 0.00% 0.00%
Invested Capital Growth		 49.99% -179.33% 38.51% -12.17% -42,177.78% 0.00%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Q/Q Growth		 -1.37% -19.54% 9.73% -66.62% 0.00% 0.00%
EBIT Q/Q Growth		 -4.18% -17.74% 9.71% -65.41% 0.00% 0.00%
NOPAT Q/Q Growth		 -4.15% -17.71% 9.71% -65.92% 0.00% 0.00%
Net Income Q/Q Growth		 -4.47% -15.90% 11.24% -5.77% 0.00% 0.00%
EPS Q/Q Growth		 -9.88% 56.59% -100.00% 100.00% 0.00% 0.00%
Operating Cash Flow Q/Q Growth		 -6.89% -7.62% 11.92% -9.91% -0.61% 0.00%
Free Cash Flow Firm Q/Q Growth		 -12.14% -14.53% 16.60% 0.00% 0.00% 0.00%
Invested Capital Q/Q Growth		 -4.71% -321.73% -365.99% -22.56% 0.00% 0.00%
Profitability Metrics		 - - - - - -
Gross Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBIT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Profit (Net Income) Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Tax Burden Percent		 100.26% 100.00% 100.00% 100.00% 100.00% 100.00%
Interest Burden Percent		 85.64% 85.68% 97.09% 99.55% 98.85% 97.60%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 -32.04% -44.90% -47.39% -60.29% -72.98% -81.14%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Assets (ROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Common Equity (ROCE)		 -32.04% -23.81% -2.74% -60.29% -22.91% 137.07%
Return on Equity Simple (ROE_SIMPLE)		 -28.73% -29.11% 49.02% -59.73% -48.98% 48.03%
Net Operating Profit after Tax (NOPAT)		 -73 -58 -27 -36 -29 -17
NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)		 -5.59% -7.98% -12.67% -17.23% -20.78% -22.77%
Return On Investment Capital (ROIC_SIMPLE)		 -23.62% -23.78% - - - -
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
R&D to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)		 -104 -84 -39 -52 -42 -24
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -103 -88 -39 -51 -42 -24
Valuation Ratios		 - - - - - -
Price to Book Value (P/BV)		 3.55 2.32 0.00 0.69 4.55 0.00
Price to Tangible Book Value (P/TBV)		 3.55 2.32 0.00 0.69 4.55 0.00
Price to Revenue (P/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.00 0.00 13,834.11
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 -1.02 -1.03 -1.04 -1.05 -1.03 -1.00
Leverage Ratio		 1.08 1.11 1.11 1.08 1.10 1.15
Compound Leverage Factor		 0.92 0.95 1.08 1.08 1.08 1.12
Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 205.35% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 268.93%
Common Equity to Total Capital		 100.00% 100.00% -105.35% 100.00% 100.00% -168.93%
Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 40.46 12.43 4.27 1.73 34.06 6.63
Noncontrolling Interest Sharing Ratio		 0.00% 46.97% 94.21% 0.00% 68.60% 268.93%
Liquidity Ratios		 - - - - - -
Current Ratio		 19.99 10.28 8.00 12.86 14.47 7.29
Quick Ratio		 19.69 9.78 7.78 12.52 14.12 6.89
Cash Flow Metrics		 - - - - - -
Free Cash Flow to Firm (FCFF)		 -77 -54 -29 -36 -25 0.00
Operating Cash Flow to CapEx		 -166,345.45% -41,120.13% -5,241.34% -389,758.33% -207,766.67% -15,626.43%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - -
Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics		 - - - - - -
Invested Capital		 -3.65 -7.30 -2.61 -4.25 -3.79 0.01
Invested Capital Turnover		 0.00 0.00 0.00 0.00 0.00 0.00
Increase / (Decrease) in Invested Capital		 3.65 -4.68 1.64 -0.46 -3.80 0.00
Enterprise Value (EV)		 786 317 182 -31 296 125
Market Capitalization		 1,099 570 108 59 384 76
Book Value per Share		 $6.34 $5.97 ($2.92) $3.27 $4.85 ($69.54)
Tangible Book Value per Share		 $6.34 $5.97 ($2.92) $3.27 $4.85 ($69.54)
Total Capital		 310 246 73 86 84 29
Total Debt		 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 -313 -253 -76 -90 -88 -29
Capital Expenditures (CapEx)		 0.04 0.15 0.61 0.01 0.02 0.14
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -11 -13 -7.50 -4.79 -4.06 -2.48
Debt-free Net Working Capital (DFNWC)		 302 240 68 85 84 26
Net Working Capital (NWC)		 302 240 68 85 84 26
Net Nonoperating Expense (NNE)		 16 13 11 15 12 6.58
Net Nonoperating Obligations (NNO)		 -313 -253 -76 -90 -88 -29
Total Depreciation and Amortization (D&A)		 0.74 -4.31 0.22 0.25 0.22 0.01
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Adjustments		 - - - - - -
Adjusted Basic Earnings per Share		 ($1.89) ($2.01) $0.06 ($51,384,002.37) ($3.53) $0.00
Adjusted Weighted Average Basic Shares Outstanding		 47.07M 35.55M 26.29M 26.29M 17.58M 0.00
Adjusted Diluted Earnings per Share		 ($1.89) ($2.01) $0.06 ($51,384,002.37) ($3.53) $0.00
Adjusted Weighted Average Diluted Shares Outstanding		 47.07M 35.55M 26.39M 26.29M 17.58M 0.00
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 ($51,384,002.37) ($3.53) $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 49.00M 41.35M 26.23M 21.66M 13.92M 0.00
Normalized Net Operating Profit after Tax (NOPAT)		 -73 -58 -27 -36 -29 -17
Normalized NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Pre Tax Income Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt Service Ratios		 - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - -
Dividend Payout Ratio		 0.00% -12.20% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% -12.20% 0.00% -1.12% -4.15% -8.51%

Quarterly Metrics And Ratios for Enliven Therapeutics

This table displays calculated financial ratios and metrics derived from Enliven Therapeutics' official financial filings.

Metric Q4 2024 Q3 2024 Q2 2024 Q1 2024 Q4 2023 Q3 2023 Q2 2023 Q1 2023 Q4 2022 Q3 2022
Period end date 12/31/2024 9/30/2024 6/30/2024 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023 12/31/2022 9/30/2022
Growth Metrics		 - - - - - - - - - -
Revenue Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Growth		 -5.69% -0.14% -16.46% -62.50% -142.08% -140.64% -133.05% -89.27% 29.45% 20.26%
EBIT Growth		 -18.29% -11.27% -18.23% -58.29% -123.73% -121.89% -123.31% -89.19% 29.38% 20.06%
NOPAT Growth		 -18.33% -11.63% -22.20% -58.28% -123.64% -121.77% -123.31% -89.19% 29.10% 19.95%
Net Income Growth		 -19.67% -11.49% -19.31% -54.43% -102.83% -96.79% -88.11% -69.85% 33.31% 22.66%
EPS Growth		 -58.62% 5.88% 0.00% 32.50% 90.03% 84.40% 85.66% 73.42% -100.00% -341.89%
Operating Cash Flow Growth		 -37.82% 23.29% -69.60% -12.08% -53.25% -146.53% -69.13% -101.18% 34.76% 40.86%
Free Cash Flow Firm Growth		 -100.19% -20.55% 39.56% -41.93% -28.30% -17.85% -55.41% -102.25% 8.59% -61.65%
Invested Capital Growth		 49.99% -101.45% -765.37% -314.87% -179.33% -276.17% 10.25% -40.57% 38.51% 128.33%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Q/Q Growth		 1.39% -7.70% 8.43% -8.68% 6.57% -25.25% -27.77% -61.91% 7.13% -21.31%
EBIT Q/Q Growth		 0.37% -13.41% 8.40% -14.29% 6.28% -20.50% -22.63% -61.55% 7.05% -21.27%
NOPAT Q/Q Growth		 0.64% -10.02% 5.33% -14.33% 6.26% -20.43% -22.63% -61.55% 7.05% -21.27%
Net Income Q/Q Growth		 -0.10% -16.07% 12.26% -17.39% 6.74% -24.21% -13.56% -54.18% 9.51% -18.73%
EPS Q/Q Growth		 4.17% -17.07% 24.07% -86.21% 43.14% -24.39% 48.75% 72.51% 11.01% -14.34%
Operating Cash Flow Q/Q Growth		 -41.09% 40.33% 12.53% -87.16% 21.47% -31.91% 42.19% -155.91% -26.34% 9.50%
Free Cash Flow Firm Q/Q Growth		 -30.72% -100.35% 46.47% -42.80% 21.28% -0.44% -25.71% -29.08% 27.70% -32.46%
Invested Capital Q/Q Growth		 -4.71% 53.61% -163.95% 60.99% -321.73% -253.23% 264.58% 73.74% -365.99% -4.10%
Profitability Metrics		 - - - - - - - - - -
Gross Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBIT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Profit (Net Income) Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Tax Burden Percent		 100.00% 100.00% 101.18% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Interest Burden Percent		 86.18% 85.78% 82.83% 87.49% 85.19% 85.61% 83.05% 89.68% 93.97% 96.52%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 -32.04% -30.98% -28.37% -26.14% -44.90% -38.72% -30.29% -24.03% -47.39% -54.17%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -3,758.41% 0.00% 0.00% -3,515.42%
Operating Return on Assets (OROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Assets (ROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Common Equity (ROCE)		 -32.04% -30.98% -28.37% -26.14% -23.81% -38.72% -30.29% -24.03% -2.74% -54.17%
Return on Equity Simple (ROE_SIMPLE)		 0.00% -29.55% -27.16% -25.05% 0.00% -23.60% -18.48% -15.00% 0.00% -74.07%
Net Operating Profit after Tax (NOPAT)		 -19 -19 -17 -18 -16 -17 -14 -11 -7.11 -7.65
NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)		 -1.54% -1.52% -0.92% -1.48% -2.10% -2.37% -1.55% -1.77% -2.94% -3.64%
Return On Investment Capital (ROIC_SIMPLE)		 -6.08% - - - -6.47% - - - - -
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
R&D to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)		 -27 -27 -24 -26 -23 -24 -20 -16 -10 -11
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -26 -26 -24 -27 -24 -26 -21 -16 -10 -11
Valuation Ratios		 - - - - - - - - - -
Price to Book Value (P/BV)		 3.55 4.18 3.60 2.29 2.32 2.15 3.01 1.97 0.00 1.05
Price to Tangible Book Value (P/TBV)		 3.55 4.18 3.60 2.29 2.32 2.15 3.01 1.97 0.00 1.05
Price to Revenue (P/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.00 0.00 0.00 497.16 0.00 0.00 3.70
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 -1.02 -1.01 -1.01 -1.01 -1.03 -1.00 -0.99 -1.00 -1.04 -1.02
Leverage Ratio		 1.08 1.05 1.05 1.06 1.11 1.04 1.04 1.06 1.11 1.06
Compound Leverage Factor		 0.93 0.90 0.87 0.93 0.95 0.89 0.86 0.95 1.05 1.02
Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 205.35% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% -105.35% 100.00%
Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 41.24 42.31 29.83 17.53 13.17 27.58 53.31 30.61 5.40 16.11
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 46.97% 0.00% 0.00% 0.00% 94.21% 0.00%
Liquidity Ratios		 - - - - - - - - - -
Current Ratio		 19.99 17.44 14.39 13.47 10.28 22.24 30.96 27.23 8.00 32.51
Quick Ratio		 19.69 17.14 14.13 12.80 9.78 21.81 30.38 26.70 7.78 30.97
Cash Flow Metrics		 - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -22 -17 -8.58 -16 -11 -14 -14 -11 -8.75 -12
Operating Cash Flow to CapEx		 0.00% -55,422.73% -1,021,750.00% -116,805.00% -89,157.14% -99,337.50% -13,692.05% -67,238.71% -8,064.36% -46,050.00%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - - - - -
Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics		 - - - - - - - - - -
Invested Capital		 -3.65 -3.49 -7.51 -2.85 -7.30 -1.73 1.13 -0.69 -2.61 0.98
Invested Capital Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Increase / (Decrease) in Invested Capital		 3.65 -1.76 -8.64 -2.16 -4.68 -2.71 0.11 -0.20 1.64 4.45
Enterprise Value (EV)		 786 915 787 407 317 299 561 282 182 3.63
Market Capitalization		 1,099 1,206 1,099 727 570 562 839 575 108 60
Book Value per Share		 $6.34 $6.11 $6.48 $7.68 $5.97 $6.36 $6.79 $11.11 ($2.92) $2.18
Tangible Book Value per Share		 $6.34 $6.11 $6.48 $7.68 $5.97 $6.36 $6.79 $11.11 ($2.92) $2.18
Total Capital		 310 288 305 318 246 262 279 291 73 57
Total Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 -313 -292 -312 -321 -253 -263 -278 -292 -76 -56
Capital Expenditures (CapEx)		 0.00 0.02 0.00 0.02 0.01 0.02 0.09 0.03 0.10 0.01
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -11 -12 -16 -8.39 -13 -6.95 -3.84 -5.04 -7.50 0.98
Debt-free Net Working Capital (DFNWC)		 302 280 296 312 240 257 274 287 68 57
Net Working Capital (NWC)		 302 280 296 312 240 257 274 287 68 57
Net Nonoperating Expense (NNE)		 4.35 4.21 2.73 4.55 3.46 3.80 2.63 3.23 2.44 2.90
Net Nonoperating Obligations (NNO)		 -313 -292 -312 -321 -253 -263 -278 -292 -76 -56
Total Depreciation and Amortization (D&A)		 1.06 0.79 -0.53 -0.58 -1.71 -1.91 -0.76 0.07 0.06 0.06
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Adjustments		 - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($0.46) ($0.48) ($0.41) ($0.54) ($0.29) ($0.51) ($0.41) ($0.80) ($2.91) ($0.18)
Adjusted Weighted Average Basic Shares Outstanding		 47.07M 48.27M 48.08M 42.05M 35.55M 41.03M 40.96M 18.51M 3.12M 26.29M
Adjusted Diluted Earnings per Share		 ($0.46) ($0.48) ($0.41) ($0.54) ($0.29) ($0.51) ($0.41) ($0.80) ($2.91) ($0.44)
Adjusted Weighted Average Diluted Shares Outstanding		 47.07M 48.27M 48.08M 42.05M 35.55M 41.03M 40.96M 18.51M 3.12M 26.29M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 ($4,609,000.00)
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 49.00M 48.86M 47.24M 47.04M 41.35M 41.21M 41.15M 41.11M 26.23M 26.29M
Normalized Net Operating Profit after Tax (NOPAT)		 -19 -19 -17 -18 -16 -17 -14 -11 -7.11 -7.65
Normalized NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Pre Tax Income Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt Service Ratios		 - - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% -1.65% -12.20% -14.14% -16.95% -16.97% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% -1.65% -12.20% -14.14% -16.95% -16.97% 0.00% 0.00%

Frequently Asked Questions About Enliven Therapeutics' Financials

When does Enliven Therapeutics's financial year end?

According to the most recent income statement we have on file, Enliven Therapeutics' fiscal year ends in December. Their fiscal year 2024 ended on December 31, 2024.

How has Enliven Therapeutics' net income changed over the last 5 years?

Enliven Therapeutics' net income appears to be on an upward trend, with a most recent value of -$89.02 million in 2024, rising from -$23.46 million in 2019. The previous period was -$71.58 million in 2023. See where experts think Enliven Therapeutics is headed by visiting Enliven Therapeutics' forecast page.

What is Enliven Therapeutics's operating income?
Enliven Therapeutics's total operating income in 2024 was -$104.55 million, based on the following breakdown:
  • Total Gross Profit: $0.00
  • Total Operating Expenses: $104.55 million
How has Enliven Therapeutics revenue changed over the last 5 years?

Over the last 5 years, Enliven Therapeutics' total revenue changed from $0.00 in 2019 to $0.00 in 2024, a change of 0.0%.

How much debt does Enliven Therapeutics have?

Enliven Therapeutics' total liabilities were at $15.92 million at the end of 2024, a 38.7% decrease from 2023, and a 263.2% increase since 2019.

How much cash does Enliven Therapeutics have?

In the past 5 years, Enliven Therapeutics' cash and equivalents has ranged from $4.94 million in 2019 to $124.12 million in 2024, and is currently $124.12 million as of their latest financial filing in 2024.

How has Enliven Therapeutics' book value per share changed over the last 5 years?

Over the last 5 years, Enliven Therapeutics' book value per share changed from -69.54 in 2019 to 6.34 in 2024, a change of -109.1%.


Related Companies

This page (NASDAQ:ELVN) was last updated on 5/27/2025 by MarketBeat.com Staff
From Our Partners
Market Panic: Trump Just Dropped a Bomb on Your Stocks
tock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...
American Alternative | Sponsored
White House to reset Social Security?
Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...
Altimetry | Sponsored
Everyone’s watching Nvidia right now. Here’s why I’m excited.
So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...
Timothy Sykes | Sponsored
Is President Trump Lying To You With This?
President Trump’s economic transition isn’t without hardship. But what if there were a smart, tax-free way to ...
Colonial Metals | Sponsored
Buffett’s favorite chart just hit 209% – here’s what that means for gold
A Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...
Golden Portfolio | Sponsored
A grave, grave error.
I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...
Porter & Company | Sponsored
July 2025 Rule Change to Impact Retirement Investors
There's a massive change from a new rule going into effect this July. And it's one the Big Banks are alread...
Premier Gold Co | Sponsored
Trump Exec Order 14179 is wealth “gift” to good Americans?
Is President Trump’s Executive Order 14179… A secret way to restore wealth for good citizens? If you’ve ...
Paradigm Press | Sponsored